Isoniazid resistance among rifampicin-susceptible Mycobacterium tuberculosis isolates from tuberculosis patients | Zendy

Jyoti Arora | Zendy; Ritu Singhal | Zendy; Ajoy Kumar Verma | Zendy; Gavish Kumar | Zendy; Manpreet Bhalla | Zendy; Rohit Sarin | Zendy; Vithal Prasad Myneedu | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Isoniazid resistance among rifampicin-susceptible Mycobacterium tuberculosis isolates from tuberculosis patients

Author(s) -

Jyoti Arora,

Ritu Singhal,

Ajoy Kumar Verma,

Gavish Kumar,

Manpreet Bhalla,

Rohit Sarin,

Vithal Prasad Myneedu

Publication year - 2016

Publication title -

international journal of mycobacteriology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.53

H-Index - 20

eISSN - 2212-554X

pISSN - 2212-5531

DOI - 10.1016/j.ijmyco.2016.10.007

Subject(s) - ethambutol , isoniazid , rifampicin , streptomycin , mycobacterium tuberculosis , drug resistance , medicine , tuberculosis , microbiology and biotechnology , multiple drug resistance , virology , antibiotics , biology , pathology

With the introduction of novel molecular techniques that rely on rifampicin (RIF) susceptibility, resistance to isoniazid (INH) or other first-line drugs remains undetected. Such patients are prescribed first-line antituberculosis therapy and are on RIF monodrug therapy during the continuation phase, which may lead to therapeutic failure and emergence of multidrug resistance. We aimed to study INH resistance among RIF-susceptible Mycobacterium tuberculosis (MTB) isolates from retreatment patients.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research